This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kinn, J. W. Articles by Bache, R. J. Search for Related Content PubMed PubMed Citation Articles by Kinn, J. W. Articles by Bache, R. J.

(Circulation. 1998;98:1431-1437.)
© 1998 American Heart Association, Inc.

Basic Science Reports

Effect of Platelet Activation on Coronary Collateral Blood Flow

James W. Kinn, MD; ; Robert J. Bache, MD

From the Division of Cardiology, Department of Internal Medicine, University of Minnesota Medical School, Minneapolis, Minn.

Correspondence to Robert J. Bache, MD, Division of Cardiology, Department of Internal Medicine, University of Minnesota Medical School, Box 508 UMHC, 420 Delaware St SE, Minneapolis, MN 55455. E-mail bache001{at}maroon.tc.umn.edu

Background—The platelet products thromboxane A₂ and serotonin have been shown to cause constriction of well-developed coronary collateral vessels. This study was performed to determine whether intravascular platelet activation produced with platelet activating factor (PAF) can cause a decrease in coronary collateral blood flow.

Methods and Results—Collateral vessel growth was induced by embolization of a hollow stainless steel plug into the left anterior descending coronary artery (LAD) of adult dogs. The animals were returned to the laboratory 3 to 6 weeks later for surgical instrumentation and measurement of collateral blood flow. Collateral flow was assessed by measuring retrograde blood flow from the cannulated collateral-dependent artery. PAF (10 nmol) was injected into the left main coronary artery to allow products of platelet activation to reach collateral vessels arising from the left coronary system. PAF caused a vasoconstrictor response, which became maximal 3 minutes after injection and resulted in a 40.3±7.4% decrease in retrograde blood flow (32.1±2.1 to 19.6±3.2 mL/min; P<0.05). By 15 minutes after the PAF injection, both retrograde blood flow and transcollateral resistance had returned to normal. After pretreatment with the thromboxane A₂ receptor antagonist SQ30,741, the vasoconstrictor response to PAF was abolished and, in contrast to the decrease in retrograde blood flow from PAF alone, a weak vasodilator effect was unmasked.

Conclusions—PAF caused a decrease in coronary collateral blood flow. This vasoconstrictor response required the participation of thromboxane A₂.

Key Words: blood flow • collateral circulation • platelets • thromboxane

This article has been cited by other articles:

				X. Hou, F. Gobeil Jr., A. M. Marrache, C. Quiniou, S. Brault, D. Checchin, S. G. Bernier, F. Sennlaub, J.-S. Joyal, D. Abran, et al. Increased platelet-activating factor-induced periventricular brain microvascular constriction associated with immaturity Am J Physiol Regulatory Integrative Comp Physiol, April 1, 2003; 284(4): R928 - R935. [Abstract] [Full Text] [PDF]

				M Mansaray, J.W Hynd, I Vergroesen, P.R Belcher, A.J Drake-Holland, and M.I.M Noble Measurement of coronary collateral flow and resistance in the presence of an open critical stenosis, and the response to intra-arterial thrombosis Cardiovasc Res, August 1, 2000; 47(2): 359 - 366. [Abstract] [Full Text] [PDF]